Artis BioSolutions is an integrated development and manufacturing company advancing the next generation of genetic medicines. As the first company to combine proprietary synthetic DNA manufacturing with advanced therapy development and GMP manufacturing, Artis offers a connected path from starting material to clinical production. Through its proprietary enzymatic, cell-free DNA platform and translational development expertise, the company helps partners reduce complexity, accelerate timelines, and maintain greater control across the development journey. With operations in the United States and Europe, Artis supports programs spanning cell therapy, gene therapy, mRNA, gene editing, vaccines, and other advanced therapeutic modalities. Its platform brings together synthetic DNA, process development, scale-up, and clinical GMP manufacturing under one organization, enabling innovators to move promising science toward the clinic with greater speed, rigor, and confidence. Artis transforms scientific potential into clinical reality.